Active Surveillance Prostate Cancer Video Chat, May 27th, 2026
AnCan is grateful to the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics, and Foundation Medicine.
Active Surveillance (AS) for low-risk prostate cancer involves unique challenges compared to other treatments. This online support group is designed for men and their caregivers who are currently on or considering AS. We hold four meetings monthly, recording only the second and fourth sessions. Our discussions cover a wide range of topics, including anxiety management, biopsy experiences, and the decision-making process around continuing or discontinuing AS. Newcomers are given priority to share their experiences, so we encourage you to join us.
Eric- Atlanta 8:18 PM
2nd Opinin for Biopsy links: https://ancan.org/prostate-cancer-and-gu-pathology-2nd-opinions/
Eric- Atlanta 8:22 PM
The Active Surveillor: https://howardwolinsky.substack.com
Eric- Atlanta 8:32 PM
New Prostate Cancer Guidelines and ASPI Pathway: https://ancan.org/new-prostate-cancer-guidelines-and-aspi-pathway/
Eric- Atlanta 8:39 PM
Ancan Solo Arts Heal: https://ancan.org/solo-arts-heal/ Tonight at 10:30EST
AnCan – Rick 8:52 PM
Here’s another more direct link if you’d like to listen to Laurie and myself. https://themarsh.org/soloartsheal/
Eric- Atlanta 8:53 PM
‘Threading the Clinical Needle’ on Gleason 6/GG1: A Matter of Language and Math: https://howardwolinsky.substack.com/p/threading-the-clinical-needle-on
Joe C 9:14 PM
Thanks, guys. Appreciate the discussion, information and all the good advice. I have to drop.
AnCan – Rick 9:25 PM
Cipro is the standard GU antibiotic
AnCan – Rick 9:28 PM
Gotta run over for the Solo Arts Heal tech check. Please join us at 7.30 pm Pacific https://themarsh.org/soloartsheal/ Good night, Gents…
A relatively new year, new guidelines, and new tools for prostate cancer screening and monitoring.
In recent months, the AUA updated its 2023 guidelines specifically for early detection of prostate cancer (https://www.auanet.org/guidelines-and-quality/guidelines/early-detection-of-prostate-cancer-guideline). Along with those guidelines, two other organizations have updated or developed additional tools that are beneficial to all men, regardless of where they are on the prostate cancer journey (or even those not yet on a journey).
Consider them collectively as an introduction to screening (NCCN), an AS-focused source (ASPI), and a comprehensive guide for early-stage prostate cancer.
I would not consider any of them as a standalone product for all the information a man might need. The NCCN guidelines are focused on screening and are relatively basic. ASPI’s product is focused on AS, but some may find the scope and scale of information a bit overwhelming without someone to advise and assist them. The appendix at the end of the pamphlet would be exceedingly useful for anyone beginning their prostate cancer journey. Finally, the AUA guidelines are broader and developed more for urologists.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer.
——————————————————————————————————–
2nd Thursday of each month at 8 pm Eastern in The Barniskis Room (222-583-973)
AnCan frequently recommends second opinions on prostate cancer and genitourinary (GU) pathology slides – whether it be from biopsy, surgery or another protocol. Our recommended providers are:
Active Surveillance Prostate Cancer Video Chat, May 13th, 2026
AnCan is grateful to the following sponsors for making this recording possible: Novartis, Blue Earth Diagnostics, and Foundation Medicine.
Active Surveillance (AS) for low-risk prostate cancer involves unique challenges compared to other treatments. This online support group is designed for men and their caregivers who are currently on or considering AS. We hold four meetings monthly, recording only the second and fourth sessions. Our discussions cover a wide range of topics, including anxiety management, biopsy experiences, and the decision-making process around continuing or discontinuing AS. Newcomers are given priority to share their experiences, so we encourage you to join us.
Eric- Atlanta 8:29 PM
BPH ASPI video Dr. Casey Dauw: https://aspatients.org/meeting/the-abcs-of-bph/
Eric- Atlanta 8:30 PM
Ancan Special Presentation: It Ain’t Your Grandpa’s BPH: https://ancan.org/special-presentation-it-aint-your-grandpas-bph/
Andy Douglas, FL 8:40 PM
Standard Medicare Coverage Criteria (all must be met) Medicare covers Aquablation once per patient when: prostate volume is 30–150 cc confirmed by transrectal ultrasound (TRUS), IPSS score greater than or equal to 12, maximum urinary flow rate less than or equal to15 mL/s with voided volume greater than 125 cc, and there has been failure or intolerance of at least 3 months of conventional therapy (such as alpha-blockers or 5-ARIs). The procedure must use an FDA-approved device
Rob Wood 8:42 PM
Rob Wood – Maine– aquablation questions to Mike Williams woodsinmaine@gmail.com
BJ Kap 8:59 PM
thanks guys great discussion have a good night
Eric- Atlanta 9:10 PM
Benign Prostatic Hypertrophy (BPH) Morgan McDowell, DNP, APRN, WHNP-BC, AGPCNP-BC: https://grandroundsinurology.com/benign-prostatic-hypertrophy-bph/?_hsmi=381422106&fbclid=IwZXh0bgNhZW0CMTEAc3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHicfwgnaFklEBjKzeyZafooENJ-llAD_2V-GZKdLpAKoPZvT4jXRibNOyO-y_aem_x0ohp35PKH7dhukcwFD2Tg
Mike Thompson 9:15 PM
Thanks everyone- great discussion tonight. Good night.
